Abstract
The prognostic importance of baseline urines for cocaine was examined in a randomized, placebo-controlled, twelve-week clinical trial in 165 opioid- and cocaine-dependent patients who were treated with desipramine (DMI) in combination with buprenorphine (BUP) or methadone (Meth). Patients with a cocaine-positive urine at baseline (CU+) had significantly fewer cocaine-free urines than those with a negative urine at baseline (CU-neg). The CU+ patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenergic Uptake Inhibitors / therapeutic use*
-
Adult
-
Buprenorphine / therapeutic use
-
Cocaine / urine*
-
Cocaine-Related Disorders / drug therapy*
-
Cocaine-Related Disorders / rehabilitation*
-
Desipramine / therapeutic use*
-
Dopamine Uptake Inhibitors / urine*
-
Female
-
Humans
-
Male
-
Methadone / therapeutic use
-
Middle Aged
-
Narcotic Antagonists / therapeutic use
-
Placebos
-
Predictive Value of Tests
-
Prognosis
-
Treatment Outcome
-
Urinalysis
Substances
-
Adrenergic Uptake Inhibitors
-
Dopamine Uptake Inhibitors
-
Narcotic Antagonists
-
Placebos
-
Buprenorphine
-
Cocaine
-
Desipramine
-
Methadone